Spots Global Cancer Trial Database for A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide
Official Title: A Phase Ib/IIa Clinical Study of IMM0306 fo r Injection in Combination With Lenalidomide for the Treatment of Relapsed/Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma Cell Non-Hodgkin's Lymphoma
Study ID: NCT05771883
Conditions
Study Description
Brief Summary: The objective of this study was to evaluate the safety and efficacy of IMM0306 in combination with lenalidomide in patients with relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma.
Detailed Description: Main study purpose: To assess the safety and tolerability of IMM0306 in combination with lenalidomide to determine the maximum tolerated dose (MTD) (if available) and the recommended Phase 2 dose (RP2D). Secondary study purpose 1. To assess the antitumor efficacy of IMM0306 in combination with lenalidomide. 2. To assess the immunogenicity of IMM0306 in combination with lenalidomide. 3. To evaluate the pharmacokinetic (PK) profile of IMM0306 in combination with lenalidomide. Exploratory study purpose: 1. Explore the correlation between exposure to IMM0306 and efficacy and safety (data permitting). 2. Explore the correlation of biomarkers with safety.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
